Results 121 to 130 of about 53,202 (260)
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10018-10027, November 2026.ABSTRACT Aims The study aims (1) to evaluate the quality of diabetes care considering guideline‐recommended medical therapies, cardiometabolic factors, and self‐management of health behaviours among older adults with diabetes in Germany, and (2) to examine time trends.
Yong Du +6 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 9941-9954, November 2026.ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo +3 more
wiley +1 more source
Cardiovascular DiabetologyBackground Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have been shown to reduce cardiovascular risk and mortality in patients with type 2 diabetes mellitus (T2D), yet remain underutilized ...
Ziad Arow +8 more
doaj +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10093-10098, November 2026.ABSTRACT Aims To evaluate the effect of liraglutide on residual beta‐cell function in adults with long‐standing type 1 diabetes (T1D) and detectable C‐peptide. Materials and Methods In this randomized, blinded, placebo‐controlled trial, 18 adults with T1D duration ≥ 5 years and detectable fasting C‐peptide were assigned to liraglutide or placebo for 52
José Caballero‐Corbalán +3 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 9849-9860, November 2026.ABSTRACT Background Body composition changes during glucagon‐like peptide‐1 (GLP‐1)‐based therapy remain incompletely characterized, particularly regarding their effects on adiposity, muscle quantity, and muscle quality. We conducted a systematic review and meta‐analysis using a predefined physiological framework to evaluate body composition ...
Maria Luizza Lopes Menezes +6 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10163-10172, November 2026.ABSTRACT Aims Type 2 diabetes drives the progression of metabolic dysfunction‐associated steatohepatitis (MASH). We evaluated whether antidiabetic therapy, specifically adding sodium–glucose cotransporter 2 (SGLT2) inhibitor to a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), improves liver histology in adults with biopsy‐proven MASH and type 2 ...
Teruki Miyake +14 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10648-10663, November 2026.ABSTRACT Background Dietary linoleic acid (LA)‐rich oils reduce liver fat in healthy adults who are not otherwise undergoing weight loss strategies. Effects on the liver fat in adults with fatty liver disease are unknown. Objective The objective of this randomized double‐masked controlled trial was to compare the effects of a dietary soybean oil (SO ...
Martha A. Belury +10 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10780-10794, November 2026.ABSTRACT Objective Treatment response in type 2 diabetes (T2D) varies widely among individuals. This study aimed to quantify the contributions of clinical characteristics and genetic predisposition as measured through partitioned polygenic risk scores (pPRS) to variation in glycemic response to glucose‐lowering therapies.
S. Garg +4 more
wiley +1 more source